Regeneron Pharmaceuticals Inc（REGN）の株式分析REGNRegeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The Company is accelerating drug development using its proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. VelociSuite consists of VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, VelociHum, and other related technologies. Its marketed products include EYLEA (aflibercept); Dupixent (dupilumab); Libtayo (cemiplimab); Ordspono (odronextamab); Kevzara (sarilumab); Itepekimab; Lynozyfic, and others. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Regeneron Pharmaceuticals Inc is a good buy right now due to its current price of $746.54, which is below the analyst price targets ranging from $737 to $960. The recent expansion of the partnership with Sanofi, which includes a $1 billion upfront payment and potential milestone payments of up to $7 billion, significantly strengthens Regeneron's financial position. Additionally, the company has a strong gross margin of 86.56% in the latest quarter, indicating robust profitability. However, the RSI is at 45.655, suggesting it is nearing oversold territory, which could indicate a potential rebound in price. The main risk is the recent 20-day price change of -4.47%, indicating some volatility in the short term.

26 analysts cover REGN: 13 rate it Buy, 12 Hold and 1 Sell. The average price target is 808.50.